DMK Pharmaceuticals Statistics
Total Valuation
DMK Pharmaceuticals has a market cap or net worth of 10. The enterprise value is -6.27 million.
| Market Cap | 10 |
| Enterprise Value | -6.27M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
DMK Pharmaceuticals has 10.09 million shares outstanding.
| Shares Outstanding | 10.09M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +174.99% |
| Owned by Insiders (%) | 0.18% |
| Owned by Institutions (%) | 0.00% |
| Float | 10.08M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.28 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.66 |
Financial Position
The company has a current ratio of 0.58
| Current Ratio | 0.58 |
| Quick Ratio | 0.50 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | -127.25 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -102.41% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 301,641 |
| Profits Per Employee | -1.87M |
| Employee Count | 12 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 5.66 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.98% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -99.98% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.06 |
| Relative Strength Index (RSI) | 43.19 |
| Average Volume (20 Days) | 5,627 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.36 |
Income Statement
In the last 12 months, DMK Pharmaceuticals had revenue of 3.62 million and -22.41 million in losses. Loss per share was -6.39.
| Revenue | 3.62M |
| Gross Profit | -1.35M |
| Operating Income | -17.28M |
| Pretax Income | -21.16M |
| Net Income | -22.41M |
| EBITDA | -16.65M |
| EBIT | -17.28M |
| Loss Per Share | -6.39 |
Balance Sheet
The company has 6.66 million in cash and 63,209 in debt, giving a net cash position of 6.60 million or 0.65 per share.
| Cash & Cash Equivalents | 6.66M |
| Total Debt | 63,209 |
| Net Cash | 6.60M |
| Net Cash Per Share | 0.65 |
| Equity (Book Value) | -4.96M |
| Book Value Per Share | -0.52 |
| Working Capital | -5.59M |
Cash Flow
In the last 12 months, operating cash flow was -9.38 million and capital expenditures -91,494, giving a free cash flow of -9.47 million.
| Operating Cash Flow | -9.38M |
| Capital Expenditures | -91,494 |
| Free Cash Flow | -9.47M |
| FCF Per Share | -0.94 |
Margins
| Gross Margin | -37.30% |
| Operating Margin | -477.45% |
| Pretax Margin | -584.45% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -261.75% |
Dividends & Yields
DMK Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -63.90% |
| Shareholder Yield | -63.90% |
| Earnings Yield | -639,428,300.00% |
| FCF Yield | -93,858,417.09% |
Stock Splits
The last stock split was on May 22, 2023. It was a reverse split with a ratio of 0.0142857.
| Last Split Date | May 22, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.0142857 |
Scores
DMK Pharmaceuticals has an Altman Z-Score of -56.52. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -56.52 |
| Piotroski F-Score | n/a |